Could ETQ's share price be soon to benefit from their developments with the new UVGI Nightingale Mobile Air Filtration Product.

New UVGI air filtration product

In November 2002, the ETQ announced its new Nightingale UVGI air filtration product, to be produced by a new joint-venture company, UVGI Systems Limited, owned 55% by the Group and 45% by Suvair Limited. This rapid response mobile air filtration unit is capable of killing the MRSA super bug and other airborne pathogens.

The UVGI unit has widespread application where there is need to keep
air free of dangerous live bacteria, viruses, and fungal spores, including
hospitals, schools, cruise liners, aircraft, food processing, and military
applications.

The UVGI unit uses a high intensity Ultra Violet Germicidal Irradiation ('UVGI')
filter, which has been designed to control harmful and dangerous airborne
pathogens, such as Anthrax, Tuberculosis, and Staphylococcus aureus, the
causative agent in MRSA. The filtration system is combined with use of high
intensity Ultra Violet light, which inactivates micro organisms by disrupting
their DNA structure.

Tests of a prototype at the Defence Science Technology Laboratory ('Dstl') at
Porton Down, the centre for excellence for the Ministry of Defence, showed that
the UVGI unit captured and/or destroyed more than 99.9% of Bacillus subtilis
spores, a simulant for Anthrax bacteria.

Since November, second generation units have been developed, which will go on
applications testing at an NHS Trust Hospital in December 2003, following
building completion of its new haematology unit. It is also anticipated the
UVGI unit will shortly go on laboratory testing in the United States with
contractors nominated by the Department of Homeland Security.

Concern seems to be hotting up on the T.V. news that the MRSA super bug is still killing and disabling people visiting or as patients in NH Trust hospitals. It would be surprising if NH Trust hospital do not notice and Buy this product before they get to many expensive law suits for compensation claims.

Definitely a stock that could soon be heading north. Worth buying in but DYOR

L.

RELATED NEWS LINKS

Sky News Sun 28th Sept 03 - NEW ANTIBIOTICS WARNING
BBC World News Thurs 4th December 03 - Hospital infections: Case studies
BBC World News Fri 5th Dec 03 - 'Superbug' crackdown is launched
BBC World News Monday 22nd Dec 03 - Superbugs lurk in intensive care
Sky News Sun 14th Dec 03 - SUPERBUG CARRIED BY PETS
BBC World News Thurs 26th Feb 04 - Superbug deaths increase 15-fold
BBC World News Mon 22nd March 04 - MRSA superbug hits more children
BBC World News Fri 2nd April 04 - Superbug outbreak in cardiac ward
BBC World News Thurs 8th April 04 - NHS faces superbug legal claims
BBC World News Sun 6th June 04 - Government 'complacent' over MRSA
BBC World News Fri 18th June 04 - Superbug deaths 'set to double'
BBC World News Thurs 1st July 04 - Holland's tough line combats MRSA
BBC World News Thurs 1st July 04 - Overcrowded hospitals breed MRSA
ITV.com Fri 9th July 04 - Mother's MRSA nightmare
ITV.com Fri 9th July 04 - 'MRSA superbug has done this to me'
ITV.com Fri 9th July 04 - Precautions you can take against MRSA
Sky News Sun 11th July 04 - WAR DECLARED ON MRSA
BBC UK News Mon 12th July 04 - Drive to fight hospital superbugs

Apple

Read carefully...

http://www.crp-bangladesh.org/specials/mrsa.htm

AGM STATEMENT AT NOON TOMORROW.ANY VIEWS?

at market waiting for update re nhs talks if this is not mention more selling.cheers woodie

just as i wrote this morning no news on nhs, selling kicked in.up then down bearish tone still dominent.cheers woodie

some seriously pissed off comments over at ample.

patience is being tested.

not even sufficient positive spin to keep up any hopes. Poor PR

promises promises. No further sales or agreements could be accepted if there was more info on how they are pursuing these, the steps they are having to go through or some timescale to their expectations.

GN

There was hype about MRSA but UVGI is not a solution for MRSA.

NHS has other priorities.

UVGI would be useful on aircraft to SLOW the spread of Bird Flu which could kill more than the 1918 Flu epidemic that killed 40Million

BUT there is no sign that it will be taken up.

Well, here we are near 4p again.

Will ETQ come up with a strategy to make money out of UVGI technology?

or will it fall through 4p?

Any views on the 1,000,000 share trade this afternoon. Sell or Buy? At 3.75 it looks more like a sell, with the bid at 4.25 and offer at 4. However no affect on share price at all. I know it 'only' represents 37.5k but it does stand out like a sore thumb. Its also surrounded by sells today although small bits and pieces.

GN

There was also a "buy" of 1,000,000 @ 4.20 at 16.39, was this a coincidence or am I missing something obvious?

Signed a distributor.

I see that they are still trying to kid people that it is the solution to MRSA even though it is not much use for that bug.

http://www.moneyam.com/action/news/showArticle?id=498681

apple - you are partially correct. The Nightingale system is designed to kill 99.8% of all airborne viruses and bacteria, but the greatest means by which MRSA spreads is through direct contact with infected surfaces due to poor hygiene within hospitals. That said, MRSA can still spread as an airborne bug. But lets not worry about the hype. If the share price rises on misdirected information then I'm happy with that.

as a very modest shareholdr, i agree with apple. im only in the share because of potential commercial activity. NOT because i beleve in the products. i have been saying for months ( elsewhere )that simple hygiene is all that is required. the trouble these days is that when a problem appears ANYWHERE, a huge entourage appears with all kinds of technical solutions. when confronted by such dilemmas i remember a "space age" problem.

astonauts needed to write in space, in zero gravity, upside down, etc. america spent hundreds of millions of dollars deleloping a suitable pen.

the russians used PENCILS.

i partly agree about containing the bugs through hygene,but if they are becoming resistent then the ultra violet will at least do the airbourne job,where as the cleanseness would not always work,

Airborn spread of MRSA is sooooooo unlikely that there is no point in buying UVGI systems for it.

The only danger of airborne spread is coughing or sneezing over an open wound & no gadget will catch those bacteria in mid air.

Just ask your local hospital, don't take my opinion or that of anyone anyone else on a message board.

UVGI is a useful technology but not for MRSA.

The current portable product would be very usful for a mobile operating theatre as long as it was piped into it to cause outward airflow.

No sign yet of such an application.

The movement of airborne infections is far more complex than you think. Colds and flu are predominately spread through the air and are very common among society, simply because it is a very easy and efficient way for a virus to spread.

Bacteria and viruses spores dont just fall to the ground when you breathe. Although invisible to the naked eye, just walking through a room swirls the surrounding air and heat thermals from electrical appliances and heaters constantly keep air movement circulating.

The use of an extraction or circulation system utilising UVGI would have a positive impact on the spread airborne infection.

True bradleym

but not MRSA

As for Colds and Flu, spending money in other ways eg Flu jabs can have a much bigger impact.

This is some good news as IMO a company with an annual turnover Euro 500 million the FlaktWoods Group has the clout to give Nightingale market penetration over a large global presence!

Energy Technique PLC
04 November 2004

Energy Technique PLC ('The Company') is pleased to announce the signing of a
major distribution agreement between its subsidiary company, UVGI Ltd., which
manufactures the award winning Nightingale air filtration product, and
FlaktWoods AB of Jonkoping, Sweden, part of the FlaktWoods Group of Zurich,
Switzerland.

The deal gives FlaktWoods AB the rights to distribute the Nightingale and
related products in Scandinavia.

Energy Technique Chairman Gerard Thompson said 'This distribution agreement for
the Nightingale is a real breakthrough for the Company, and marks a further
important step in our drive to market the unit to counter the threat of the
hospital superbug, MRSA, and other dangerous germs. FlaktWoods is highly
regarded in the industry as innovative and creative. We are confident that,
over time, this relationship will develop into an important driving force in
specialised air handling in the UK and Europe.'

The Nightingale uses a combination of high intensity Ultra Violet Germicidal
Irradiation (UVGI) and airflow to destroy the DNA structure of harmful airborne
germs such as MRSA, anthrax, tuberculosis, and flu. It is already in use in a US
hospital, and has been installed for trials with a UK NHS trust. Tests at the
Porton Down facility of the Health Protection Agency have shown it to be more
than 99.9% effective.

FlaktWoods Group is a world leader in ventilation and air handling. It has a
complete 'product portfolio' covering virtually every function within an air
handling system with specialized products for different application areas.

With an annual turnover of Euro 500 million, the FlaktWoods Group has
manufacturing and engineering operations in Sweden, Finland, UK, France, Italy,
Belgium, Poland, Russia, Dubai, India, Korea, Japan, Australia and in the
Americas.

It employs 3,200 worldwide and has operations and representation in some 95
countries. Over 200,000 buildings use its air handling units, including some
300 hospitals.


This information is provided by RNS
The company news service from the London Stock Exchange

Airborne transmission is known to be the route of infection for diseases such as tuberculosis and aspergillosis. It has also been implicated in nosocomial outbreaks of MRSA, Acinetobacter spp. and Pseudomonas spp. Despite this there is much scepticism about the role that airborne transmission plays in nosocomial outbreaks. This paper investigates the airborne spread of infection in hospital buildings, and evaluates the extent to which it is a problem. It is concluded that although contact-spread is the principle route of transmission for most infections, the contribution of airborne micro-organisms to the spread of infection is likely to be greater than is currently recognised. This is partly because many airborne micro-organisms remain viable while being non-culturable, with the result that they are not detected, and also because some infections arising from contact transmission involve the airborne transportation of micro-organisms onto inanimate surfaces.

Although most nosocomial infections are associated with person-to-person contact, it has been estimated that the airborne route of transmission accounts for between 10% and 20% of endemic nosocomial infections (4). However, with the exception of tuberculosis, where the airborne route of infection has long been recognised, the contribution made by airborne pathogens towards nosocomial infection has often been underestimated. Despite this, it is now recognised that a number of nosocomial pathogens, including Aspergillus spp., Acinetobacter spp and MRSA can be transmitted by the airborne route.

Infectious microorganisms can enter the air by a variety of routes. They can be violently dispersed into the atmosphere as respiratory droplets/droplet nuclei through sneezing or coughing, or released into the air on skin squamae which are continually shed by room occupants.

Other activities, such as bed making, release large quantities of microorganisms into the atmosphere. In one study, it was found that the airborne bioburden in a patient room exceeded 6000 colony forming units per cubic meter of air (cfu/m3) during vigorous bed making (5).

thanks Chunki,

apart from the need for a glossary I think thats clarified things very well.

Wahtever people think of individual pathogens and how they are spread the fact remains that a huge number of infections / illnesses/ deaths are caused by airborne pathogens of a huge variety of forms and these need to be dealt with/protected against.

Now, I wonder when someone will invent a suitable gismo........


GN